There is merit in conducting a third party audit of CMS reports prior to attestation and submission to ensure data integrity, completeness and compliance to changing regulations.
The issuance of the OIG Special Fraud Alert and the increasing oversight of the DOJ must prompt Drug and Device Manufacturers to follow stringent measures before submitting their reports to CMS to protect themselves from possible sanctions and to maintain their credibility in the industry.
Hence, similar to a financial audit it is imperative that pharmaceutical compliance teams appreciate and embody the merits of conducting an audit for ensuring transparency.
Schedule an Appointment
Publish your transparency reports without calling attention. Get your report audited in detail by our experts
- Rigorous QA/QC process
- Data collection made easy
- Spend Identification
- Data Overview
- Data Benchmarking
- Physician/Teaching Hospitals detail verification
- Risk of cost dilution analysis
- Verify Source transactions
- Analyze spend in our Analytics and Monitoring tool